Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMS-F021 SAD and MAD in Healthy Participants
NCT07790770Phase 1Recruiting
- Sponsor
- Dermavant Sciences
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMS-F021 Gel in skin and soft tissue infection (SSTI) (4 arms), sponsored by Dermavant Sciences. Primary endpoints: Change from baseline to each visit point in vital signs at 10 days, Incidence rate of abnormal findings in comprehensive systemic physical examination at 10 days and 3 more. Started Jul 2026; status: recruiting.
02
Drugs
CMS-F021 Gel
03
Conditions
skin and soft tissue infection (SSTI)
Beyond the preview
Go deeper on NCT07790770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790770.